Medtronic management check

MDT · Health Care · Health Care Equipment · CEO Geoff Martha

Filings as of

45
Management score, ranked 454th of 487 · 57th of 60 in Health Care2 good · 2 to watch · 3 flaggedStrongest: clean books · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$74Peers$97

    What $100 became since fiscal 2022

    2029th
    Detail

    $100 invested at the start of fiscal 2022 grew to $74, against $97 for the peer group the company picked itself.

  • Flag

    Does pay follow performance?

    Pay moved against returns20222026

    Pay actually paid $100 value, each on its own scale

    203rd
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.59 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Flag

    What does the CEO cost owners?

    477822.4% of net income

    $22.9m pay · $5k net income, FY2026

    0.1%1%3%10%
    016th
    Detail

    $22.9m of reported pay in fiscal 2026, against $5k of net income.

  • Watch

    Do they own the stock?

    CEO stake ≈ 1.2 years of pay

    277,866 shares ≈ $26.4m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $6.5m sold

    3840th
    Detail

    The CEO holds 277,866 shares, directly or through trusts (unvested awards not counted): about 1.2 years of pay. Light activity: no buys, $6.5m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 1.4bn2025 · 1.3bn

    Diluted shares −1.6% a year; flagged above +2%

    0%10%20%

    Stock pay 1.3% of revenue

    7062nd
    Detail

    Diluted shares changed -1.6% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.

  • Watch

    Is leadership stable?

    12 leadership filings in 3 years

    12 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Geoff Martha

    6540th
    Detail

    CEO in the pay table: Geoff Martha. 12 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed August 17, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$13.0m$26.1m$10020222023202420252026$74$97

Pay tied most to Revenue Growth

Other key measuresEPSTotal Shareholder ReturnFree Cash Flow

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2026Geoff Martha$22.9m$22.5m$7.3m$74$97$5k
2025Geoff Martha$21.2m$26.1m$5.6m$98$149$5k
2024Geoff Martha$20.1m$11.1m$7.6m$90$135$4k
2023Geoff Martha$15.4m$3.3m$5.4m$99$131$4k
2022Geoff Martha$17.9m$3.0m$7.6m$110$124$5k

Insiders and the CEO's stakeQuiet

Chairman and CEO
Geoffrey Martha
Shares held
277,866
At that filing's price
≈ $26.4m
Latest Form 4
Oct 15, 2026

Light activity: no buys, $6.5m sold in six months. 3 of 6 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldGeoffrey MarthaChairman and CEO · 10b5-1 plan$4.8mOct 15, 2026
  • SoldMichael MarinaroEVP, Pres MedSurg and Americas · 10b5-1 plan$1.0mOct 15, 2026
  • SoldHarry Skip KiilEVP & President Cardiovascular$476kSep 16, 2026
  • SoldMatthew R. WalterSVP, Chief HR Officer · 10b5-1 plan$258kJul 8, 2026

Leadership and governance on file

20222023202420252026Leadership 16Votes 6
All 16 filings

Latest shareholder vote results: Oct 19, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $27.5bn returned to owners in buybacks and dividends, 125319110% of net income, and $2.0bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$3.4bn$6.8bn20212022202320242025Shares1.35bn1.33bn1.33bn1.29bn1.29bn
Show the figures
Fiscal year20212022202320242025
Revenue$31.7bn$31.2bn$32.4bn$33.5bn$36.4bn
Net income$5k$4k$4k$5k$5k
Stock-based pay$359.0m$355.0m$393.0m$429.0m$457.0m
Buybacks$2.5bn$645.0m$2.1bn$3.2bn$1.0bn
Dividends$3.4bn$3.6bn$3.7bn$3.6bn$3.6bn
Diluted shares1351m1333m1330m1290m1288m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.